DEUTERIERTE IVACAFTOR-DERIVATE
European patent · EP2709986 · In force
Register entry
- Publication number
- EP2709986
- Application number
- EP12725197
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- May 17, 2012
- Published
- Mar 26, 2014
- Granted
- Mar 22, 2017
- Protection ends at the latest
- May 16, 2032
- Next annual fee due
- May 31, 2027
- IPC classes
- C07D 215/56 (2006.01)C07B 59/00 (2006.01)A61K 31/47 (2006.01)A61P 11/12 (2006.01)
- Priority
- US 201161487497 P 18.05.2011
- PCT application
- PCT/US2012/038297 17.05.2012
- PCT publication
- WO2012/158885 22.11.2012
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Jun 1, 2026
Change
Published in Swissreg on 01.06.2026
- Jun 1, 2025
Change
Published in Swissreg on 01.06.2025
- Jun 2, 2024
Change
Published in Swissreg on 02.06.2024
- Jun 9, 2023
Change
Published in Swissreg on 09.06.2023
- Apr 15, 2020
Transferred
- Owner
- Concert Pharmaceuticals Inc., 99 Hayden Avenue, Lexington, MA 02421, USA → Vertex Pharmaceuticals (Europe) Limited, 2 Kingdom Street, London W2 6BD, United Kingdom
Published in Swissreg on 15.04.2020
- Apr 21, 2017
Agent entered
- Representative
- Isler & Pedrazzini AG, Postfach 1772, 8027 Zürich
Published in Swissreg on 21.04.2017
- Mar 22, 2017
Granted
Published in Swissreg on 22.03.2017
Parties
Inventor
MORGAN, Adam, J.
Ashland MA 01721, US
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.